Fig. 11: C16 in combination with Ang-1 treatment supressed the activated astrocytes. | npj Parkinson's Disease

Fig. 11: C16 in combination with Ang-1 treatment supressed the activated astrocytes.

From: Adjusting vascular permeability, leukocyte infiltration, and microglial cell activation to rescue dopaminergic neurons in rodent models of Parkinson’s disease

Fig. 11

a–l The activated astrocytes in the SN were stained with GFAP (green). C16 (c, h), Ang-1 (d, i), and especially the C + A treatment (e, j) suppressed the proliferation of astrocytes in vehicle-treated PD models (b, g). Panel k shows astrocytes in the normal control group. Panel l shows the proliferated glial cells and glial scar (red arrow in l) in the vehicle-treated group in high magnification. Scale bar = 100 µm. m Stereological analysis of GFAP + cells. a p < 0.05 versus the normal control group; b p < 0.05 versus the vehicle group; c p < 0.05 versus the C16-treated group; d p < 0.05 versus the Ang-1-treated group. GFAP, glial fibrillary acidic protein; C16, peptide (KAFDITYVRLKF) that can selectively bind integrin ανβ3; Ang-1 angiopoietin-1.

Back to article page